CMPX Compass Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CMPX

Price (delayed)

$1.17

Market cap

$210.7M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.39

Enterprise value

$184.31M

?
Relative Growth: Rel. Growth: 6
Relative Strength: Rel. Strength: 2
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 6
Highlights
The EPS rose by 13% year-on-year and by 2.5% since the previous quarter
CMPX's debt is down by 2.7% year-on-year
The equity has soared by 78% YoY but it has contracted by 11% from the previous quarter
Compass Therapeutics's quick ratio has soared by 53% YoY but it has decreased by 41% from the previous quarter
The net income has declined by 18% year-on-year and by 8% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.compasstherapeutics.com
Peers: AMGN GILD VRTX REGN

Key stats

What are the main financial stats of CMPX

CMPX stock price

How has the Compass Therapeutics stock price performed over time
Intraday
-5.65%
1 week
-36.07%
1 month
-51.25%
1 year
-65.33%
YTD
-78.21%
QTD
-46.58%

Financial performance

How have Compass Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$81.09M
Net income
-$73.45M
Gross margin
N/A
Net margin
N/A
The operating income has decreased by 20% YoY and by 8% from the previous quarter
The net income has declined by 18% year-on-year and by 8% since the previous quarter

Price vs fundamentals

How does CMPX's price correlate with its fundamentals

Growth

What is Compass Therapeutics's growth rate over time

Valuation

What is Compass Therapeutics stock price valuation
P/E
N/A
P/B
1.27
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS rose by 13% year-on-year and by 2.5% since the previous quarter
The equity has soared by 78% YoY but it has contracted by 11% from the previous quarter
CMPX's price to book (P/B) is 64% lower than its last 4 quarters average of 3.7 and 44% lower than its 5-year quarterly average of 2.4

Efficiency

How efficient is Compass Therapeutics business performance
The ROIC has grown by 32% YoY
The return on equity is up by 27% year-on-year and by 2.5% since the previous quarter
Compass Therapeutics's return on assets has increased by 25% YoY

Dividends

What is CMPX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CMPX.

Financial health

How did Compass Therapeutics financials performed over time
The total assets has soared by 63% YoY but it has decreased by 7% from the previous quarter
Compass Therapeutics's quick ratio has soared by 53% YoY but it has decreased by 41% from the previous quarter
CMPX's debt is 94% smaller than its equity
The equity has soared by 78% YoY but it has contracted by 11% from the previous quarter
CMPX's debt to equity is down by 45% year-on-year but it is up by 20% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.